![Context Therapeutics Inc](/common/images/company/N_CNTX.png)
Context Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and ... Context Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. Show more
Announced acquisition of CT-95, a mesothelin x CD3 bispecific antibody Claudio Dansky Ullmann, M.D. named Chief Medical Officer Cash and cash equivalents of $101.5 million as of June 30, 2024...
Company announces appointments of Dr. Claudio Dansky Ullmann as CMO and Ms. Karen Andreas as VP, Clinical Operations Appointments support the development of the Company’s two clinical-stage T...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.19 | -7.11610486891 | 2.67 | 2.7 | 2.41 | 82165 | 2.53440597 | CS |
4 | 0 | 0 | 2.48 | 2.75 | 2.01 | 86309 | 2.39680294 | CS |
12 | 0.46 | 22.7722772277 | 2.02 | 2.75 | 1.352 | 258509 | 2.12714354 | CS |
26 | 1.34 | 117.543859649 | 1.14 | 2.75 | 1.03 | 405184 | 1.84452189 | CS |
52 | 1.43 | 136.19047619 | 1.05 | 2.75 | 0.77 | 222091 | 1.7787811 | CS |
156 | -1.96 | -44.1441441441 | 4.44 | 10.87 | 0.47 | 796335 | 3.76976341 | CS |
260 | -1.96 | -44.1441441441 | 4.44 | 10.87 | 0.47 | 796335 | 3.76976341 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.